Navigation Links
Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
Date:8/30/2010

talix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system.  Protalix's ProCellEx (TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.  Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease.  Protalix's new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
For more information on Protalix, visit http://www.protalix.com.

Safe Harbor StatementTo the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements, including statements relating to the perceived effects of dual listing on the market for our common stock, are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Factors that might cause material differences include, among others, risks relating to the trading of our common stock on the Tel Aviv Stock Exchange or the NYSE Amex, risks relating to our continued compliance with the rules of the Tel Aviv Stock Exchange and the NYSE Amex and other
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Protalix Announces Successful GMP Manufacturing Audit by Israels Ministry of Health
2. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
3. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
4. Northwest Biotherapeutics Secures $700,000 Equity Financing
5. Oxygen Biotherapeutics, Inc. Expands Board of Directors
6. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
11. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... pace of growing computing power could be sustained for ... from the UK,s National Physical Laboratory (NPL) that is ... observed that the density of transistors on an integrated ... time to achieve this, but experts believed that when ...
... OMAHA, Neb., Dec. 9 Transgenomic, Inc.,(OTC Bulletin ... been,awarded an accreditation by the Commission on Laboratory ... on the results of a recent,on-site inspection. Transgenomic ... laboratories nationwide. , Craig Tuttle, CEO ...
... Kingdom and MONTREAL, Dec. 9 /PRNewswire-FirstCall/ - ProMetic ... U.K.-based subsidiary, ProMetic BioSciences Ltd ("PBL"), has signed ... world-leading European Biopharmaceutical company estimated to be worth ... years, with first shipment delivery starting this quarter. ...
Cached Biology Technology:Transgenomic Receives Accreditation From College of American Pathologists 2Transgenomic Receives Accreditation From College of American Pathologists 3ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company 2ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company 3
(Date:4/24/2014)... State University and the University of North Carolina at ... could help identify arterial plaque that is at high ... stroke. , At issue is the plaque that builds ... plaque are deemed "vulnerable," meaning that they are more ... heart attack or stroke. , "Existing state-of-the-art technologies are ...
(Date:4/24/2014)... RICHLAND, Wash. A common plant puts out a welcome ... the mat,s molecular mix. , The study published this week ... reveals new targets during the battle between microbe and ... team showed that the humble and oft-studied plant Arabidopsis ... from a pathogen. It,s as if a hostile army were ...
(Date:4/23/2014)... German . Man ... difference between sexes depends on one single element of the genome: ... two sexual chromosomes are X and Y, whereas women have two ... morphological and physiological differences between males and females. , But this ... the X and Y were identical, until the Y started to ...
Breaking Biology News(10 mins):New ultrasound device may add in detecting risk for heart attack, stroke 2How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Male or female? 2Male or female? 3
... the diet for Thanksgiving? Turkey with all the fixings ... their goals, according to a new Cornell University review ... willpower every day. "We,re slaves to our environment," ... psychology at Cornell, who co-authored the article with graduate ...
... WASHINGTON, Nov. 16, 2011 A new episode ... Challenges/Chemistry Solutions" podcast series spins a real-life tale ... major barrier to the use of gene therapy in ... largest scientific society explains in non-technical language that gene ...
... DURHAM, New Hampshire, November 16, 2011 A study ... Thursday, Nov. 17, concludes that forests influence temperature, and ... Hollinger, a plant physiologist with the U.S. Forest Service,s ... Xuhui Lee, a professor of meteorology at the Yale ...
Cached Biology News:New American Chemical Society podcast: Genetically-engineered spider silk for gene therapy 2Forests cooler or warmer than open areas depending on latitude, study finds 2
... The transformation of Saccharomyces cerevisiae, as ... routine procedure in many molecular biology laboratories. ... high efficiencies with plasmid and linear DNAs ... has made routine plasmid transformations and library ...
...
... jetSI-ENDO-FluoF is a ... nm; emission at 520 nm), ... These reagents are used to ... investigate the intracellular delivery and ...
... R&D Systems Cell and Tissue Staining Kits ... a broad range of histological and cytological ... primary IgG antibodies manufactured by either R&D ... is based on the formation of the ...
Biology Products: